News Regeneron forges CAR-T R&D partnership with bluebird bio Deal combines Regeneron's receptor tech with CAR-T biotech's expertise
News Spectacular results for bluebird's gene therapy in thalassem... Patients with the rare blood disorders transfusion-dependent β-thalassemia (TDT) have shown spectacular results in clinical trials of bluebird bio's gene therapy, raising hopes the treatmen
News Scotland's TC BioPharm joins bluebird to develop next-gen CA... US cancer biotech bluebird bio has joined with TC BioPharm in a collaboration focused on gamma delta CAR-T cells.
News More good news for Bluebird Bio with CALD gene therapy Bluebird Bio has presented encouraging data from its gene therapy treatment for t
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.